May 10th 2017 Transenterix Inc announced finanical results and business update for Q1 2017. The financial results included
-Sale of 1 Senhance robot in Germany
-$17M new credit line that allowed the company to refinance all existing debt.
The company has about $48M in cash which is enough to fund operations through Q2 2018 including launch of the Senhance sales in the U.S. if the robot is approved by the FDA
The company continued building sales infrastrucutre in Europe. In total the Company placed 7 robots for demo and training purposes covering the major markets - the U.K., Germany, France, and Italy.